Empagliflozin/linagliptin/metformin
| Combination of | |
|---|---|
| Empagliflozin | SGLT2 inhibitor |
| Linagliptin | DPP-4 inhibitor |
| Metformin | Anti-diabetic biguanide |
| Clinical data | |
| Trade names | Trijardy XR |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Empagliflozin/linagliptin/metformin, sold under the brand name Trijardy XR, is a fixed-dose combination medication used for the treatment of type 2 diabetes.[2] It is a combination of empagliflozin, linagliptin, and metformin. Empagliflozin/linagliptin/metformin was approved for use in the United States in January 2020.[3][4]
Adverse effects
[edit]To reduce the risk of developing ketoacidosis (a serious condition where the body produces high levels of blood acids called ketones) after surgery, the FDA has approved changes to the prescribing information for SGLT2 inhibitor diabetes medications, recommending they be temporarily stopped before scheduled surgery. Empagliflozin should each be stopped at least three days before scheduled surgery.[5]
Symptoms of ketoacidosis include nausea, vomiting, abdominal pain, tiredness, and trouble breathing.[5]
History
[edit]The combination preparation was developed and marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.[6][7]
References
[edit]- ^ "Trijardy XR- empagliflozin, linagliptin, metformin hydrochloride tablet, extended release". DailyMed. Archived from the original on 25 December 2021. Retrieved 24 December 2021.
- ^ Kim ES, Deeks ED (September 2015). "Empagliflozin/Linagliptin: A Review in Type 2 Diabetes". Drugs. 75 (13): 1547–57. doi:10.1007/s40265-015-0457-z. PMID 26323340. S2CID 27675087.
- ^ "Trijardy XR: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 23 May 2020. Retrieved 11 February 2020.
- ^ "US FDA approves only triple-combination tablet with Jardiance for adults with type 2 diabetes" (Press release). Eli Lilly and Company. 27 January 2020. Archived from the original on 13 February 2020. Retrieved 10 February 2020 – via PR Newswire.
- ^ a b "FDA revises labels of SGLT2 inhibitors for diabetes to include warning". U.S. Food and Drug Administration. 19 March 2020. Archived from the original on 7 June 2020. Retrieved 6 June 2020.
This article incorporates text from this source, which is in the public domain.
- ^ "US FDA approves only triple-combination tablet with Jardiance for adults with type 2 diabetes" (Press release). Boehringer Ingelheim. 27 January 2020. Archived from the original on 13 February 2020. Retrieved 10 February 2020.
- ^ "Trijardy XR (empagliflozin, linagliptin, and metformin hydrochloride extended-release tablets), for oral use" (PDF). Boehringer Ingelheim. Archived from the original on 13 February 2020. Retrieved 10 February 2020.
